TRIP13 Antibody (C-4): sc-514314
- TRIP13 Antibody (C-4) is a mouse monoclonal IgG2b κ, cited in 2 publications, provided at 200 µg/ml
- raised against amino acids 1-180 mapping at the N-terminus of TRIP13 of human origin
- Anti-TRIP13 Antibody (C-4) is recommended for detection of TRIP13 of mouse, rat and human origin by WB, IP, IF and ELISA
- Anti-TRIP13 Antibody (C-4) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgG2b BP-HRP are the preferred secondary detection reagents for TRIP13 Antibody (C-4) for WB applications. These reagents are now offered in bundles with TRIP13 Antibody (C-4) (see ordering information below).
QUICK LINKS
SEE ALSO...
TRIP13 Antibody (C-4) is a mouse monoclonal IgG2b kappa light chain antibody that detects TRIP13 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). anti-TRIP13 antibody (C-4) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TRIP13, also known as thyroid hormone receptor interactor 13 or 16E1BP, plays a crucial role in the regulation of gene expression as a transcription factor. TRIP13 interacts with the ligand-binding domain of thyroid hormone receptors, which are essential for mediating the effects of thyroid hormones on gene expression. TRIP13 is unique among TRIP proteins as TRIP13 does not require thyroid hormone for receptor interaction, suggesting a distinct regulatory mechanism. TRIP13 has been implicated in the interaction with the human papillomavirus type 16 E1 protein, indicating a potential role in tumor suppression. TRIP13 consists of 432 amino acids and exists in two isoforms due to alternative splicing, highlighting TRIP13′s complexity and potential for diverse functional roles in cellular processes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TRIP13 Antibody (C-4) References:
- TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. | Zhang, G., et al. 2019. Br J Cancer. 121: 1069-1078. PMID: 31740732
- TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. | Agarwal, S., et al. 2020. Mol Oncol. 14: 3007-3029. PMID: 33037736
- TRIP13 predicts poor prognosis in clear cell renal cell carcinoma. | Kowalewski, A., et al. 2020. Am J Cancer Res. 10: 2909-2918. PMID: 33042625
- TRIP13 exerts a cancer-promoting role in cervical cancer by enhancing Wnt/β-catenin signaling via ACTN4. | Liu, X., et al. 2021. Environ Toxicol. 36: 1829-1840. PMID: 34061428
- TRIP13 Participates in Immediate-Early Sensing of DNA Strand Breaks and ATM Signaling Amplification through MRE11. | Jeong, H., et al. 2022. Cells. 11: PMID: 36552858
- Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma. | Xu, L., et al. 2023. Leukemia. 37: 1576-1579. PMID: 37157015
- TRIP13 overexpression in hepatocellular carcinoma: implications for poor prognosis and immune cell infiltration. | Xue, J., et al. 2023. Discov Oncol. 14: 176. PMID: 37740123
- Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. | Afaq, F., et al. 2024. Neoplasia. 47: 100951. PMID: 38039923
- Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. | Mittal, K., et al. 2024. Commun Biol. 7: 426. PMID: 38589567
- TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis. | Chotiner, JY., et al. 2024. Elife. 12: PMID: 39207914
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRIP13 Antibody (C-4) | sc-514314 | 200 µg/ml | $322.00 | |||
TRIP13 Antibody (C-4): m-IgG Fc BP-HRP Bundle | sc-526356 | 200 µg Ab; 10 µg BP | $361.00 | |||
TRIP13 Antibody (C-4): m-IgG2b BP-HRP Bundle | sc-549717 | 200 µg Ab; 10 µg BP | $361.00 | |||
TRIP13 Antibody (C-4) AC | sc-514314 AC | 500 µg/ml, 25% agarose | $424.00 | |||
TRIP13 Antibody (C-4) HRP | sc-514314 HRP | 200 µg/ml | $322.00 | |||
TRIP13 Antibody (C-4) FITC | sc-514314 FITC | 200 µg/ml | $336.00 | |||
TRIP13 Antibody (C-4) PE | sc-514314 PE | 200 µg/ml | $349.00 | |||
TRIP13 Antibody (C-4) Alexa Fluor® 488 | sc-514314 AF488 | 200 µg/ml | $364.00 | |||
TRIP13 Antibody (C-4) Alexa Fluor® 546 | sc-514314 AF546 | 200 µg/ml | $364.00 | |||
TRIP13 Antibody (C-4) Alexa Fluor® 594 | sc-514314 AF594 | 200 µg/ml | $364.00 | |||
TRIP13 Antibody (C-4) Alexa Fluor® 647 | sc-514314 AF647 | 200 µg/ml | $364.00 | |||
TRIP13 Antibody (C-4) Alexa Fluor® 680 | sc-514314 AF680 | 200 µg/ml | $364.00 | |||
TRIP13 Antibody (C-4) Alexa Fluor® 790 | sc-514314 AF790 | 200 µg/ml | $364.00 |